Dendrimers: Amazing Platforms for Bioactive Molecule Delivery Systems

Overview

Journal Materials (Basel)

Publisher MDPI

Date 2020 Jan 30

PMID 31991703

Citations 31

Authors

Claudia Sandoval-Yanez

Cristian Castro Rodriguez

Affiliations

Soon will be listed here.

Abstract

Today, dendrimers are the main nanoparticle applied to drug delivery systems. The physicochemical characteristics of dendrimers and their versatility structural modification make them attractive to applied as a platform to bioactive molecules transport. Nanoformulations based on dendrimers enhance low solubility drugs, arrival to the target tissue, drugs bioavailability, and controlled release. This review describes the latter approaches on the transport of bioactive molecules based on dendrimers. The review focus is on the last therapeutic strategies addressed by dendrimers conjugated with bioactive molecules. A brief review of the latest studies in therapies against cancer and cardiovascular diseases, as well as future projections in the area, are addressed.

Citing Articles

Theoretical and Experimental Analyses of the Interfacial Mechanism of Dendrimer-Doxorubicin Complexes Formation.

Jachimska B, Goncerz M, Wolski P, Meldrum C, Lustyk L, Panczyk T Mol Pharm. 2024; 21(11):5892-5904.

PMID: 39436101 PMC: 11539063. DOI: 10.1021/acs.molpharmaceut.4c00941.

Strategies for transportation of peptides across the skin for treatment of multiple diseases.

Bhavsar J, Kasture K, Salvi B, Shende P Ther Deliv. 2024; 16(1):63-86.

PMID: 39411995 PMC: 11703487. DOI: 10.1080/20415990.2024.2411943.

A Comprehensive Review on Repurposing the Nanocarriers for the Treatment of Parkinson's Disease: An Updated Patent and Clinical Trials.

Khan S, Haider M CNS Neurol Disord Drug Targets. 2024; 24(3):181-195.

PMID: 39400019 DOI: 10.2174/0118715273323074241001071645.

Biocompatible Glycopolymer-PLA Amphiphilic Hybrid Block Copolymers with Unique Self-Assembly, Uptake, and Degradation Properties.

Green K, Kulkarni A, Jankoski P, Newton T, Derbigny B, Clemons T Biomacromolecules. 2024; 25(10):6681-6692.

PMID: 39276065 PMC: 11480976. DOI: 10.1021/acs.biomac.4c00885.

Dendrimers-Novel Therapeutic Approaches for Alzheimer's Disease.

Mroziak M, Kozlowski G, Kolodziejczyk W, Pszczolowska M, Walczak K, Beszlej J Biomedicines. 2024; 12(8).

PMID: 39200363 PMC: 11351976. DOI: 10.3390/biomedicines12081899.

References

Maji R, Omolo C, Agrawal N, Maduray K, Hassan D, Mokhtar C . pH-Responsive Lipid-Dendrimer Hybrid Nanoparticles: An Approach To Target and Eliminate Intracellular Pathogens. Mol Pharm. 2019; 16(11):4594-4609. DOI: 10.1021/acs.molpharmaceut.9b00713. View

Diaz C, Benitez C, Vidal F, Barraza L, A Jimenez V, Guzman L . Cytotoxicity and in vivo plasma kinetic behavior of surface-functionalized PAMAM dendrimers. Nanomedicine. 2018; 14(7):2227-2234. DOI: 10.1016/j.nano.2018.07.005. View

Mello-Andrade F, Cardoso C, Ribeiro E Silva C, Chen-Chen L, Melo-Reis P, de Lima A . Acute toxic effects of ruthenium (II)/amino acid/diphosphine complexes on Swiss mice and zebrafish embryos. Biomed Pharmacother. 2018; 107:1082-1092. DOI: 10.1016/j.biopha.2018.08.051. View

Leong N, Mehta D, McLeod V, Kelly B, Pathak R, Owen D . Doxorubicin Conjugation and Drug Linker Chemistry Alter the Intravenous and Pulmonary Pharmacokinetics of a PEGylated Generation 4 Polylysine Dendrimer in Rats. J Pharm Sci. 2018; 107(9):2509-2513. DOI: 10.1016/j.xphs.2018.05.013. View

Zhang X, Li Y, Hu C, Wu Y, Zhong D, Xu X . Engineering Anticancer Amphipathic Peptide-Dendronized Compounds for Highly-Efficient Plasma/Organelle Membrane Perturbation and Multidrug Resistance Reversal. ACS Appl Mater Interfaces. 2018; 10(37):30952-30962. DOI: 10.1021/acsami.8b07917. View

Ma T, Kam K, Yan B, Lam Y . Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010; 160(6):1273-92. PMC: 2938800. DOI: 10.1111/j.1476-5381.2010.00750.x. View

Selvakumaran S, Muhamad I . Evaluation of kappa carrageenan as potential carrier for floating drug delivery system: Effect of cross linker. Int J Pharm. 2015; 496(2):323-31. DOI: 10.1016/j.ijpharm.2015.10.005. View

Chan C, Jing J, Xiao W, Tan Z, Lv Q, Yang J . Enhanced Intestinal Permeability of Bufalin by a Novel Bufalin-Peptide-Dendrimer Inclusion through Caco-2 Cell Monolayer. Molecules. 2017; 22(12). PMC: 6149814. DOI: 10.3390/molecules22122088. View

Vergara-Jaque A, Comer J, Monsalve L, Gonzalez-Nilo F, Sandoval C . Computationally efficient methodology for atomic-level characterization of dendrimer-drug complexes: a comparison of amine- and acetyl-terminated PAMAM. J Phys Chem B. 2013; 117(22):6801-13. DOI: 10.1021/jp4000363. View

10.

Kuruvilla S, Tiruchinapally G, Kaushal N, ElSayed M . Effect of N-acetylgalactosamine ligand valency on targeting dendrimers to hepatic cancer cells. Int J Pharm. 2018; 545(1-2):27-36. DOI: 10.1016/j.ijpharm.2018.04.028. View

11.

Sadeghi-Kiakhani M, Safapour S . Functionalization of poly(amidoamine) dendrimer-based nano-architectures using a naphthalimide derivative and their fluorescent, dyeing and antimicrobial properties on wool fibers. Luminescence. 2015; 31(4):1005-12. DOI: 10.1002/bio.3065. View

12.

Yamashita S, Katsumi H, Sakane T, Yamamoto A . Bone-targeting dendrimer for the delivery of methotrexate and treatment of bone metastasis. J Drug Target. 2018; 26(9):818-828. DOI: 10.1080/1061186X.2018.1434659. View

13.

Marquez-Miranda V, Abrigo J, Rivera J, Araya-Duran I, Aravena J, Simon F . The complex of PAMAM-OH dendrimer with Angiotensin (1-7) prevented the disuse-induced skeletal muscle atrophy in mice. Int J Nanomedicine. 2017; 12:1985-1999. PMC: 5357082. DOI: 10.2147/IJN.S125521. View

14.

Urzua J, Torneiro M . Divergent Synthesis of Porous Tetraphenylmethane Dendrimers. J Org Chem. 2017; 82(24):13231-13238. DOI: 10.1021/acs.joc.7b02302. View

15.

Wang F, Porter M, Konstantopoulos A, Zhang P, Cui H . Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy. J Control Release. 2017; 267:100-118. PMC: 5723209. DOI: 10.1016/j.jconrel.2017.09.026. View

16.

Saini K, Prabhuraj R, Bandyopadhyaya R . Development of Mesoporous Silica Nanoparticles of Tunable Pore Diameter for Superior Gemcitabine Drug Delivery in Pancreatic Cancer Cells. J Nanosci Nanotechnol. 2019; 20(5):3084-3096. DOI: 10.1166/jnn.2020.17381. View

17.

Maly J, Stanek O, Frolik J, Maly M, Ennen F, Appelhans D . Biocompatible Size-Defined Dendrimer-Albumin Binding Protein Hybrid Materials as a Versatile Platform for Biomedical Applications. Macromol Biosci. 2016; 16(4):553-66. DOI: 10.1002/mabi.201500332. View

18.

Sherje A, Jadhav M, Dravyakar B, Kadam D . Dendrimers: A versatile nanocarrier for drug delivery and targeting. Int J Pharm. 2018; 548(1):707-720. DOI: 10.1016/j.ijpharm.2018.07.030. View

19.

Otto D, de Villiers M . All-atomistic molecular dynamics (AA-MD) studies and pharmacokinetic performance of PAMAM-dendrimer-furosemide delivery systems. Int J Pharm. 2018; 547(1-2):545-555. DOI: 10.1016/j.ijpharm.2018.06.033. View

20.

Li L, Wang C, Huang Q, Xiao J, Zhang Q, Cheng Y . A degradable hydrogel formed by dendrimer-encapsulated platinum nanoparticles and oxidized dextran for repeated photothermal cancer therapy. J Mater Chem B. 2020; 6(16):2474-2480. DOI: 10.1039/c8tb00091c. View